Biogen CEO Pick Vounatsos Suggests A Return To Commercial Focus
Biogen’s Chief Commercial Officer Michel Vounatsos will succeed CEO George Scangos effective Jan. 6. The appointment of the longtime Merck executive appears to suggest a renewed emphasis on the commercial landscape for a big biotech that has recently played up R&D.
You may also be interested in...
Vir’s George Scangos, Westlake Village BioPartners’ Sean Harper, Kronos Bio’s Norbert Bischofberger, Scorpion’s Axel Hoos and Eikon’s Roy Baynes discuss the experiences they bring and the challenges they have faced in the transition from large drug makers to small biotechs.
Median tenure of large cap US biotech CEOs has decreased from 11 years in 2007 to one year in 2017, Leerink analyst Geoffrey Porges determined in an analysis of seven biotechs over 15 years.
The company is under pressure from investors to add new pipeline assets, but stronger than expected initial sales of Spinraza helped to assuage near-term growth concerns.